Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | YAP1 | P46937 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.45 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.45 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.45 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.45 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234783 | 0.92 | CTSS (0.59) | CTSSPOLBKMT2ACTSLPSMB11 | |
| Leucine SCHEMBL3816835 | 0.92 | CTSS (0.51) | CTSSMMEACECPA1ACE2 | |
| SCHEMBL234112 | 0.91 | CTSS (0.45) | CTSSMMEACECPA1ACE2 | |
| Leucine SCHEMBL1406209 | 0.91 | CTSS (0.54) | CTSSMMEACECPA1ACE2 | |
| SCHEMBL2299523 | 0.87 | CTSS (0.50) | CTSSMMEACECPA1ACE2 | |
| SCHEMBL234602 | 0.85 | CTSS (0.49) | CTSSPOLBKMT2ACTSLPSMB11 | |
| Leucine SCHEMBL3820155 | 0.83 | CTSS (0.45) | CTSSMMEACECPA1ACE2 | |
| Leucine SCHEMBL3812485 | 0.83 | CTSS (0.59) | CTSSPOLBKMT2ACTSLPSMB11 | |
| Leucine SCHEMBL1406207 | 0.82 | CTSS (0.47) | CTSSMMEACECPA1ACE2 | |
| Leucine SCHEMBL1406330 | 0.82 | CTSS (0.62) | CTSSPOLBKMT2ACTSLPSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| EP-1355910-B1 | FORMULATION OF BORONIC ACID COMPOUNDS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | claimed |
| EP-2251344-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | claimed |
| EP-0788360-B3 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | MILLENNIUM PHARM INC (US) | 2009-08-12 | — | — | EP | claimed |
| US-7531526-B2 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | claimed |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| US-7109323-B2 | lyophilization of an aqueous mixture comprising a boronic add compound and a compound having at least two hydroxyl groups produces a stable composition that readily releases the boronic acid compound upon dissolution in aqueous media | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-09-19 | — | — | US | claimed |
| EP-1627880-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| US-20050282742-A1 | Formulation of boronic acid compounds | Government of the USA, represented by the Secretary,Dept. of Health and Human Services (US) | 2005-12-22 | — | — | US | claimed |
| EP-1312609-A1 | Boronic ester and acid compounds, synthesis and uses | Millennium Pharmaceuticals, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20020188100-A1 | Formulation of boronic acid compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| US-20020169114-A1 | Formulation of boronic acid compounds | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-11-14 | — | — | US | claimed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | claimed |
| WO-2002059130-A1 | FORMULATION OF BORONIC ACID COMPOUNDS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-08-01 | — | — | WO | claimed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | claimed |
| US-5780454-A | Boronic ester and acid compounds | PROSCRIPT, INC. (US) | 1998-07-14 | — | — | US | claimed |
| EP-0788360-A4 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT INC (US) | 1998-05-06 | — | — | EP | claimed |
| EP-0788360-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1997-08-13 | — | — | EP | claimed |
| WO-1996013266-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | PROSCRIPT, INC. (US) | 1996-05-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188100-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | CTSS 4167/4885MME 2075/4885ACE 1110/4885 |
| US-20050282742-A1 | Formulation of boronic acid compounds | SLC10A2, BTD, SLC10A1 | CTSS 4167/4885MME 2075/4885ACE 1110/4885 |
| US-20150072942-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CTSS 2481/4885MME 557/4885ACE 2375/4885 |
| US-20020169114-A1 | Formulation of boronic acid compounds | SLC5A1, FBP1, BBC3 | CTSS 3297/4885MME 3411/4885ACE 3493/4885 |
| US-20090247731-A1 | BORONIC ESTER AND ACID COMPOUNDS, SYNTHESIS AND USES | BCL6, BCAP31, CD79B | CTSS 2481/4885MME 557/4885ACE 2375/4885 |
| US-20080132678-A1 | Boronic ester and acid compounds, synthesis and uses | BCL6, BCAP31, CD79B | CTSS 2481/4885MME 557/4885ACE 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.